Tailwinds' Take: while this news comes suddenly and will likely cause some selling in the stock, we view it as constructive. Mark Day has never gotten the traction needed with financing and, frankly, our communications with him have been...
Tailwinds' Take: Bioasis appears to have done the necessary pre-clinical work to attract interest from partners. While still early stage, it's apparent that the platform has significant promise and I expect to see more deals in the near future. GUILFORD,...
Every year for the past 36 years, Byron Wien has put out a list of “Top 10 Surprises” for the coming year. The list is comprised of potential macroeconomic events that have, according to Mr. Wien,...
Tailwinds' Take: having emerged from their silent period, Bioasis appears to be very excited about the data they are generating as they start opening their kimono to investors. Needing money soon, my belief is they have a...
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM  platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of...
This weekend we'll be hanging our stockings on the mantel. Come Christmas morning, they'll be lying on the floor, overflowing with presents. At least, that's what has traditionally happened. There always remains the risk of finding your stockings filled...
Tailwinds' Take: this long awaited news is significant for Bioasis and should spark relief in the shares. Expect to see the Company move towards a listing in the US, which would be accompanied by either a financing (most likely)...
October has a reputation for being a bad month to own stocks. For the current generation of investors, this reputation was earned primarily from several disastrous meltdowns. These include Black Monday in 1987 when the market lost 23% in...
Tailwinds' Take: a long anticipated licensing deal is likely a major sigh of relief for shares of BIOAF. While small in size, a $1M upfront fee signals that they have made substantial progress. Which may also be signaling that...
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.